Evidence map›Paper›PMID 37941016›Full record

ReviewInfectious agents and cancer2023

Association of naturally acquired type-specific HPV antibodies and subsequent HPV re-detection: systematic review and meta-analysis.

Kana Yokoji, Katia Giguère, Talía Malagón, Minttu M Rönn, Philippe Mayaud, Helen Kelly, Sinead Delany-Moretlwe, Mélanie Drolet, Marc Brisson, Marie-Claude Boily and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Infectious agents and cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 4 countries.

Kana YokojiDepartment of Epidemiology and Biostatistics, School of Population and Global Health, McGill University, 2001 Avenue McGill College, Suite 1200, Montreal, QC, H3A 1G1, Canada.
Katia GiguèreInstitut national de santé publique du Québec, Quebec City, Canada.
Talía MalagónDivision of Cancer Epidemiology, Gerald Bronfman Department of Oncology, McGill University, Montreal, Canada.
Minttu M RönnDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, USA.
Philippe MayaudDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
Helen KellyDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
Sinead Delany-MoretlweWits RHI, University of Witwatersrand, Johannesburg, South Africa.
Mélanie DroletCentre de recherche du CHU de Québec - Université Laval, Quebec City, Canada.
Marc BrissonCentre de recherche du CHU de Québec - Université Laval, Quebec City, Canada.
Marie-Claude BoilyMRC Center for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Mathieu Maheu-GirouxDepartment of Epidemiology and Biostatistics, School of Population and Global Health, McGill University, 2001 Avenue McGill College, Suite 1200, Montreal, QC, H3A 1G1, Canada. mathieu.maheu-giroux@mcgill.ca.
McGill University · CACentre hospitalier de l'Université Laval · CALondon School of Hygiene & Tropical Medicine · GBHarvard Global Health Institute · USImperial College London · GBInstitut National de Santé Publique du Québec · CAUniversity of the Witwatersrand · ZA

Funding

Medical Research Council MR/R015600/1MRC Centre for Global Infectious Disease Analysis MR/R015600/1
6 · The paper itself

Abstract

backgroundUnderstanding the role of naturally acquired (i.e., infection-induced) human papillomavirus (HPV) antibodies against reinfection is important given the high incidence of this sexually transmitted infection. However, the protective effect of naturally acquired antibodies in terms of the level of protection, duration, and differential effect by sex remains incompletely understood. We conducted a systematic review and a meta-analysis to (1) strengthen the evidence on the association between HPV antibodies acquired through past infection and subsequent type-specific HPV detection, (2) investigate the potential influence of type-specific HPV antibody levels, and (3) assess differential effects by HIV status.

methodsWe searched Embase and Medline databases to identify studies which prospectively assessed the risk of type-specific HPV detection by baseline homologous HPV serostatus among unvaccinated individuals. Random-effect models were used to pool the measures of association of naturally acquired HPV antibodies against subsequent incident detection and persistent HPV positivity. Sources of heterogeneity for each type were assessed through subgroup analyses stratified by sex, anatomical site of infection, male sexual orientation, age group, and length of follow-up period. Evidence of a dose-response relationship of the association between levels of baseline HPV antibodies and type-specific HPV detection was assessed. Finally, we pooled estimates from publications reporting associations between HPV serostatus and type-specific HPV detection by baseline HIV status.

resultsWe identified 26 publications (16 independent studies, with 62,363 participants) reporting associations between baseline HPV serostatus and incident HPV detection, mainly for HPV-16 and HPV-18, the most detected HPV type. We found evidence of protective effects of baseline HPV seropositivity and subsequent detection of HPV DNA (0.70, 95% CI 0.61-0.80, N

conclusionWe did not find evidence that naturally acquired HPV antibodies protect against subsequent HPV positivity in males and provide only modest protection among females for HPV-16. One potential limitation to the interpretation of these findings is potential misclassification biases due to different causes.

Indexed as

Cervical cancerHIV/AIDSHuman papillomavirusInfectionMeta-analysisNatural immunity

Identifiers

PMID37941016
PMCPMC10631102
OpenAlexW4388493678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.